The head-to-heads that actually matter.
20 editorial comparisons across GLP-1 drugs, healing peptides, longevity compounds, and growth-hormone secretagogues. Each cites primary trial data and settles what the evidence actually shows.
GLP-1 drugs10
Semaglutide vs liraglutide: the new GLP-1 vs the original, compared
Liraglutide (Saxenda / Victoza) was the first GLP-1 approved for obesity. Semaglutide surpassed it on every dimension that matters. Here's why, and when liraglutide still makes sense.
Semaglutide (injection) vs Rybelsus (oral): the same molecule, different delivery
Both are semaglutide. One is a weekly injection (Ozempic, Wegovy); the other is a daily tablet (Rybelsus). Here's why that matters and why it doesn't.
Retatrutide vs CagriSema: the two next-generation obesity drugs, compared
Both target ~20%+ weight loss. One is a single-molecule triple agonist from Lilly; the other is a two-molecule amylin/GLP-1 combo from Novo Nordisk. The mechanisms and development paths diverge.
Ozempic vs Mounjaro: the T2D labels of the two biggest GLP-1 drugs
Both are approved for type 2 diabetes. Different molecules, different mechanisms, meaningfully different HbA1c and weight outcomes. Here's the clinical picture.
Tirzepatide vs orforglipron: the injectable dual-agonist vs the oral GLP-1 pill
One is the largest-efficacy approved obesity drug; the other is the first small-molecule oral GLP-1 heading for FDA submission. Different tradeoffs for different patients.
Tirzepatide vs retatrutide: the approved dual-agonist vs the investigational triple
Tirzepatide is the heaviest-hitting approved obesity drug today. Retatrutide's Phase 2 numbers push even further. Here's what's known, what's not, and what the Phase 3 TRIUMPH readouts could change.
Zepbound vs Wegovy: the side-by-side on obesity's two dominant drugs
Both are FDA-approved for chronic weight management. They're made by different companies, built on different receptor mechanisms, and produce different average weight loss. Here's the head-to-head, cited.
Ozempic vs Wegovy: same drug, different label — here's what that means
Both are semaglutide. Same molecule, same manufacturer. Different approvals, different doses, different insurance outcomes. The distinction matters more than you'd think.
CagriSema vs tirzepatide: the next-generation obesity combo, compared
Novo's amylin/GLP-1 combination versus Lilly's dual-agonist tirzepatide. The REDEFINE trial data is in — here's what it actually shows.
Tirzepatide vs semaglutide: what the trials actually show
The two dominant GLP-1 weight-loss drugs compared on efficacy, side effects, cost, and dosing — with the primary-source trial data cited inline.
Healing peptides3
BPC-157 vs GHK-Cu: two biohacker favorites, very different evidence bases
Both are Category 2 research peptides. Their evidence profiles, use cases, and plausible mechanisms have essentially nothing in common. Here's the honest contrast.
Thymosin alpha-1 vs BPC-157: immune modulation vs tissue repair, evidence-graded
Two frequently-marketed Category 2 peptides with entirely different therapeutic targets and very different evidence pedigrees.
BPC-157 vs TB-500: the two halves of the 'Wolverine Stack' compared
Two research peptides routinely marketed for injury recovery. Different mechanisms, overlapping hype, similarly thin human evidence. Here's what each actually has going for it.
Longevity1
Growth / GH4
Ipamorelin vs MK-677: selective peptide vs oral small molecule, same receptor
Both activate the ghrelin receptor to stimulate growth hormone release. One's a peptide injection, the other's a daily pill. The trade-offs are bigger than the mechanism difference suggests.
CJC-1295 vs ipamorelin: what each does, and why they're usually stacked
Both stimulate growth hormone release. They act via different receptors and are commonly combined. Here's what each contributes, with the caveat that neither is FDA approved and both are Category 2.
Sermorelin vs tesamorelin: the two GHRH analogs that got FDA approval
Both are synthetic GHRH analogs. One (sermorelin) is the discontinued-but-compoundable historical workhorse; the other (tesamorelin) is the currently-marketed approved drug for HIV lipodystrophy.
Sermorelin vs CJC-1295: the two GHRH analogs compared
Both stimulate endogenous growth hormone release via GHRH receptors. One has historical FDA approval and legal compounding; the other is Category 2. Mechanisms, half-lives, and regulatory paths differ meaningfully.